Oxford Bioscience Partners
What they invest in
from 2 of 2 portfolio companiesHealthtech Γ2Biotech Γ1Hardware Γ1Medical Devices Γ1
HQs:United StatesΓ2
Investments Β· 2 tracked
founders shown can be your intro pathHydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner.
BiotechHardwareHealthtechMedical DevicesNorth Billerica, US
PAUL KOWALSKI(Executive Officer)inRICHARD A. LYTLE, III(Executive Officer, Director)THOMAS D. ABERT(Executive Officer)inPATRICIA VANBLARCOM(Executive Officer)Rick Lytle(President & Chief Executive Officer)in
BoardLONG ZHAN(Director)
Co-investorsNewbury Ventures
HealthtechTewksbury, US
Lisa Mastromattei(Executive Officer)Lisa Wipperman Heine(Executive Officer)Sophia Wong(Executive Officer)Richard P. Geoffrion(Executive Officer, Director)
BoardMartien Van Osch(Director)Daniel Cole(Director)
Co-investors415 CapitalQiming Venture Partners
Fund performance Β· per public LP disclosures Β· 4
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oxford Bioscience Partners IVLPs: The Regents of the University of California | 2001 | β | -6.6% | 0.71x | 0.71x |
| Oxford Bioscience Partners IV, L.PLPs: The Regents of the University of California | 2001 | β | -6.6% | 0.71x | 0.71x |
| Oxford Bioscience Partners IIILPs: The Regents of the University of California | 1999 | β | -13.4% | 0.38x | 0.38x |
| Oxford Bioscience Partners III, L.PLPs: The Regents of the University of California | 1999 | β | -13.4% | 0.38x | 0.38x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).